miR-1301 promotes prostate cancer proliferation through directly targeting PPP2R2C

Biomedicine and Pharmacotherapy

Volumn 81, Issue , 2016, Pages 25-30

  Bi, Dongbin ^a   Ning, Hao ^a   Liu, Shuai ^a   Que, Xinxiang ^a   Ding, Kejia ^a  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Cell proliferation; MiR 1301; PPP2R2C; Prostate cancer

Indexed keywords

3 (4,5 DIMETHYL 2 THIAZOLYL) 2,5 DIPHENYLTETRAZOLIUM BROMIDE; AGAR; MESSENGER RNA; MICRORNA; MICRORNA 1301; PPP2R2C PROTEIN; PROTEIN P27; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG; MIRN1301 MICRORNA, HUMAN; PHOSPHOPROTEIN PHOSPHATASE 2; PPP2R2C PROTEIN, HUMAN;

ANCHORAGE INDEPENDENT GROWTH; ARTICLE; CANCER GROWTH; CELL GROWTH; CELL PROLIFERATION; COLONY FORMATION; CONTROLLED STUDY; G1 PHASE CELL CYCLE CHECKPOINT; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MTT ASSAY; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RNA TRANSLATION; TUMOR SUPPRESSOR GENE; CELL ADHESION; GENE EXPRESSION REGULATION; GENE SILENCING; GENETICS; MALE; METABOLISM; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROSTATE TUMOR; UPREGULATION;

BASE SEQUENCE; CELL ADHESION; CELL PROLIFERATION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; MALE; MICRORNAS; PROSTATIC NEOPLASMS; PROTEIN PHOSPHATASE 2; UP-REGULATION;

EID: 84962701565     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2016.03.043     Document Type: Article

References (20)

1. Nicoloso M.S., Spizzo R., Shimizu M., Rossi S., Calin G.A. MicroRNAs-the micro steering wheel of tumour metastases. Nat. Rev. Cancer 2009, 9(4):293-302. 10.1038/nrc2619.
2. Zhang B., Pan X., Cobb G.P., Anderson T.A. microRNAs as oncogenes and tumor suppressors. Dev. Biol. 2007, 302(1):1-12. 10.1016/j.ydbio.2006.08.028.
3. Fabian M.R., Sonenberg N., Filipowicz W. Regulation of mRNA translation and stability by microRNAs. Annu. Rev. Biochem. 2010, 79:351-379. 10.1146/annurev-biochem-060308-103103.
4. Liu Y., Ding Y., Huang J., Wang S., Ni W., Guan J., et al MiR-141 suppresses the migration and invasion of HCC cells by targeting Tia. PLoS One 2014, 9(12):e88393. 10.1371/journal.pone.0088393.
5. Zhao X.D., Lu Y.Y., Guo H., Xie H.H., He L.J., Shen G.F., et al. MicroRNA-7/NF-kappaB signaling regulatory feedback circuit regulates gastric carcinogenesis. J. Cell Biol. 2015, 210(4):613-627. 10.1083/jcb.201501073.
6. Valeri N., Braconi C., Gasparini P., Murgia C., Lampis A., Paulus-Hock V., et al. MicroRNA-135b promotes cancer progression by acting as a downstream effector of oncogenic pathways in colon cancer. Cancer Cell 2014, 25(4):469-483. 10.1016/j.ccr.2014.03.006.
7. Torre L.A., Bray F., Siegel R.L., Ferlay J., Lortet-Tieulent J., Jemal A. Global cancer statistics, 2012. CA: Cancer J. Clin. 2015, 65(2):87-108. 10.3322/caac.21262.
8. Kim W.T., Kim W.J. MicroRNAs in prostate cancer. Prostate Int. 2013, 1(1):3-9. 10.12954/PI.12011.
9. Casanova-Salas I., Rubio-Briones J., Fernandez-Serra A. Lopez-guerrero JA. miRNAs as biomarkers in prostate cancer. Clin. Trans. Oncol. 2012, 14(11):803-811. 10.1007/s12094-012-0877-0.
10. Cai S., Chen R., Li X., Cai Y., Ye Z., Li S., et al. Downregulation of microRNA-23a suppresses prostate cancer metastasis by targeting the PAK6-LIMK1 signaling pathway. Oncotarget. 2015, 6(6):3904-3917.
11. Chakravarthi B.V., Pathi S.S., Goswami M.T., Cieslik M., Zheng H., Nallasivam S., et al. The miR-124-prolyl hydroxylase P4HA1-MMP1 axis plays a critical role in prostate cancer progression. Oncotarget 2014, 5(16):6654-6669.
12. Fang L., Yang N., Ma J., Fu Y., Yang G.S. microRNA-1301-mediated inhibition of tumorigenesis. Oncol. Rep. 2012, 27(4):929-934. 10.3892/or.2011.1589.
13. Liang W.C., Wang Y., Xiao L.J., Wang Y.B., Fu W.M., Wang W.M., et al. Identification of miRNAs that specifically target tumor suppressive KLF6-FL rather than oncogenic KLF6-SV1 isoform. RNA Biol. 2014, 11(7):845-854. 10.4161/rna.29356.
14. Liu S., Patel S.H., Ginestier C., Ibarra I., Martin-Trevino R., Bai S., et al. MicroRNA93 regulates proliferation and differentiation of normal and malignant breast stem cells. PLoS Genet. 2012, 8(6):e1002751. 10.1371/journal.pgen.1002751.
15. Chu I.M., Hengst L., Slingerland J.M. The Cdk inhibitor p27 in human cancer: prognostic potential and relevance to anticancer therapy. Nat. Rev. Cancer 2008, 8(4):253-267. 10.1038/nrc2347.
16. Casimiro M.C., Velasco-Velazquez M., Aguirre-Alvarado C., Pestell R.G. Overview of cyclins D1 function in cancer and the CDK inhibitor landscape: past and present. Expert Opin. Invest. Drugs 2014, 23(3):295-304. 10.1517/13543784.2014.867017.
17. Hu P., Yu L., Zhang M., Zheng L., Zhao Y., Fu Q., et al. Molecular cloning and mapping of the brain-abundant B1gamma subunit of protein phosphatase 2A PPP2R2C, to human chromosome 4p16. Genomics 2000, 67(1):83-86. 10.1006/geno.2000.6219.
18. Fan Y.L., Chen L., Wang J., Yao Q., Wan J.Q. Over expression of PPP2R2C inhibits human glioma cells growth through the suppression of mTOR pathway. FEBS Lett. 2013, 587(24):3892-3897. 10.1016/j.febslet.2013.09.029.
19. Bluemn E.G., Spencer E.S., Mecham B., Gordon R.R., Coleman I., Lewinshtein D., et al. PPP2R2C loss promotes castration-resistance and is associated with increased prostate cancer-specific mortality. Mol. Cancer Res. 2013, 11(6):568-578. 10.1158/1541-7786.MCR-12-0710.
20. Feldman B.J., Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 2001, 1(1):34-45. 10.1038/35094009.